Identification

Name
Topiramate
Accession Number
DB00273  (APRD00237)
Type
Small Molecule
Groups
Approved
Description

Topiramate (brand name Topamax) is an anticonvulsant drug produced by Ortho-McNeil Neurologics, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. [Wikipedia]. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity. On August 2013, an extended released formulation, marketed as Trokendi XR has been approved for the management of partial onset, tonic-clonic, and Lennox-Gastaut Syndrome seizures.

Structure
Thumb
Synonyms
  • 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
  • 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
  • McN-4853
  • RWJ-17021
  • Tipiramate
  • Tipiramato
  • Topiramate
  • Topiramato
  • Topiramatum
  • TPM
External IDs
RWJ-17021-000 / USL-255 / USL255
Product Ingredients
IngredientUNIICASInChI Key
Topiramate calciumP956SY6RA61246279-00-4VNRLRDKZOMPUAG-RZTSBURASA-N
Topiramate potassiumSMU8E1YBZ3488127-51-1VEKVPJSPZRTTGR-WGAVTJJLSA-N
Topiramate sodiumN808MSN0PT488127-49-7ZUWVVMMRNQEJMW-WGAVTJJLSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act TopiramateTablet25 mgOralActavis Pharma Company2007-07-12Not applicableCanada
Act TopiramateTablet200 mgOralActavis Pharma Company2007-07-12Not applicableCanada
Act TopiramateTablet100 mgOralActavis Pharma Company2007-07-12Not applicableCanada
Gln-topiramateTablet25 mgOralGlenmark Pharmaceuticals, IncNot applicableNot applicableCanada
Gln-topiramateTablet200 mgOralGlenmark Pharmaceuticals, IncNot applicableNot applicableCanada
Gln-topiramateTablet100 mgOralGlenmark Pharmaceuticals, IncNot applicableNot applicableCanada
Q-topiramateTablet100 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-topiramateTablet25 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-topiramateTablet200 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Qudexy XRCapsule, extended release25 mg/1OralUpsher Smith Laboratories2014-04-11Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-topiramateTablet200 mgOralBgp Pharma Ulc2014-03-172015-12-31Canada
Abbott-topiramateTablet100 mgOralBgp Pharma Ulc2014-03-122015-12-31Canada
Abbott-topiramateTablet25 mgOralBgp Pharma Ulc2014-03-122015-12-31Canada
Accel-topiramateTablet25 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-topiramateTablet200 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-topiramateTablet100 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Apo-topiramateTablet25 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-topiramateTablet200 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-topiramateTablet100 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-topiramateTablet50 mgOralApotex CorporationNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
QsymiaTopiramate (23 mg/1) + Phentermine Hydrochloride (3.75 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaTopiramate (69 mg/1) + Phentermine Hydrochloride (11.25 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaTopiramate (46 mg/1) + Phentermine Hydrochloride (7.5 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
QsymiaTopiramate (92 mg/1) + Phentermine Hydrochloride (15 mg/1)Capsule, extended releaseOralVIVUS, Inc.2012-09-17Not applicableUs
International/Other Brands
Topamax
Categories
UNII
0H73WJJ391
CAS number
97240-79-4
Weight
Average: 339.362
Monoisotopic: 339.098787343
Chemical Formula
C12H21NO8S
InChI Key
KJADKKWYZYXHBB-XBWDGYHZSA-N
InChI
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
IUPAC Name
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0²,⁶]dodecan-6-yl]methyl sulfamate
SMILES
[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2

Pharmacology

Indication

Used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Qsymia® is indicated for the treatment and management of obesity.

Associated Conditions
Pharmacodynamics

Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically.

Mechanism of action

The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAA receptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
ASodium channel protein type 1 subunit alpha
inhibitor
Human
AGlutamate receptor ionotropic, kainate 1
antagonist
Human
ACarbonic anhydrase 2
inhibitor
Human
ACarbonic anhydrase 4
inhibitor
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
Absorption

Rapid with pleak plasma concentrations occurring after 2 hours and a bioavailability of 80%. The pharmacokinetic profile of the extended release formulation is non linear at 25 mg due to binding of topiramate to carbonic anhydrase in red blood cells. The peak plasma concentration was 24 hours after a single 200 mg oral dose of the extended release formulation. It is also bioequivalent to immediate-release tablet that has been administered twice-daily. Fluctuation of topiramate plasma concentrations at steady-state for Trokendi XR™ administered once-daily was approximately 26% and 42% in healthy subjects and in epileptic patients, respectively, compared to approximately 40% and 51%, respectively, for immediate-release topiramate. When topiramate is given to elderly and young adults, the maximum plasma concentration was achieved in 1 to 2 hours.

Volume of distribution
Not Available
Protein binding

15-41% (over the blood concentration range of 0.5 - 250 mg/mL). The fraction bound decreased as blood concentration increased. Carbamazepine and phenytoin do not alter the binding of immediate-release topiramate. Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%. Immediate-release topiramate does not influence the binding of sodium valproate.

Metabolism

Not extensively metabolized, 70% of the dose is eliminated unchanged in the urine. The other 30% is metabolized hepatically to six metabolites (formed by hydroxylation, hydrolysis, and glucuronidation), none of which constitute more than 5% of an administered dose. There is evidence of renal tubular reabsorption of topiramate.

Route of elimination

Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose).

Half life

19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.

Clearance
  • Plasma clearance (CL/F) =20-30 mL/min [in humans following oral administration] Clearance in adults was not affected by gender or race. Pediatric patients on adjunctive treatment exhibited a higher oral clearance compared to those on monotherapy. This may be because of concomitant administration with enzyme-inducing antiepileptic drugs.
Toxicity

Symptoms of overdose include abdominal pain, agitation, blurred vision, convulsions, depression, dizziness, double vision, drowsiness, impaired coordination, impaired mental activity, low blood pressure, reduced consciousness, severe diarrhea, sluggishness, and speech problems.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of hyperthermia and oligohydrosis can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Topiramate.Experimental
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineTopiramate may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Topiramate is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineTopiramate may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineTopiramate may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Topiramate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineTopiramate may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineTopiramate may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineTopiramate may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineTopiramate may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineTopiramate may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbemaciclibThe serum concentration of Topiramate can be increased when it is combined with Abemaciclib.Approved, Investigational
AcefyllineTopiramate may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Topiramate can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Topiramate is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Aclidinium is combined with Topiramate.Approved
AcyclovirTopiramate may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Topiramate is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Topiramate can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Topiramate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Topiramate is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Topiramate can be increased when it is combined with Albendazole.Approved, Vet Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Alcuronium.Experimental
AlectinibThe serum concentration of Topiramate can be increased when it is combined with Alectinib.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Topiramate.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Topiramate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Topiramate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Topiramate.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Topiramate is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Topiramate is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Topiramate is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Topiramate is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe serum concentration of Topiramate can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Amisulpride.Approved, Investigational
AmitriptylineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Topiramate is combined with Amitriptylinoxide.Approved, Investigational
AmlodipineThe serum concentration of Topiramate can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Topiramate.Approved, Illicit
AmodiaquineThe serum concentration of Topiramate can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of hyperthermia and oligohydrosis can be increased when Amoxapine is combined with Topiramate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Topiramate is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Amphetamine.Approved, Illicit, Investigational
AmsacrineThe serum concentration of Topiramate can be increased when it is combined with Amsacrine.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Aniracetam.Experimental
Anisotropine MethylbromideThe risk or severity of hyperthermia and oligohydrosis can be increased when Anisotropine Methylbromide is combined with Topiramate.Approved
AnnamycinThe serum concentration of Topiramate can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Topiramate can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Topiramate is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Topiramate is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Topiramate is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Topiramate is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Topiramate is combined with Arbekacin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Topiramate is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Topiramate.Approved
AstemizoleThe serum concentration of Topiramate can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Topiramate.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Topiramate can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Topiramate can be increased when it is combined with Atorvastatin.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Topiramate is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Topiramate is combined with Atracurium besylate.Approved
AtropineThe risk or severity of hyperthermia and oligohydrosis can be increased when Atropine is combined with Topiramate.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Azaperone.Investigational, Vet Approved
AzathioprineTopiramate may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Topiramate is combined with AZD-3043.Investigational
AzelastineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe serum concentration of Topiramate can be increased when it is combined with Azithromycin.Approved
AzosemideThe risk or severity of hypokalemia can be increased when Azosemide is combined with Topiramate.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Topiramate.Approved
Bafilomycin A1The serum concentration of Topiramate can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Topiramate can be increased when it is combined with Bafilomycin B1.Experimental
BamifyllineTopiramate may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of hyperthermia and oligohydrosis can be increased when Benactyzine is combined with Topiramate.Withdrawn
BendroflumethiazideThe risk or severity of hypokalemia can be increased when Bendroflumethiazide is combined with Topiramate.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Topiramate is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of hyperthermia and oligohydrosis can be increased when Benzatropine is combined with Topiramate.Approved
BenziloneThe risk or severity of hyperthermia and oligohydrosis can be increased when Benzilone is combined with Topiramate.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe risk or severity of hyperthermia and oligohydrosis can be increased when Benzquinamide is combined with Topiramate.Withdrawn
BenzthiazideThe risk or severity of hypokalemia can be increased when Benzthiazide is combined with Topiramate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Topiramate is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Topiramate can be increased when it is combined with Bepridil.Approved, Withdrawn
BevoniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Bevonium is combined with Topiramate.Experimental
BicalutamideThe serum concentration of Topiramate can be increased when it is combined with Bicalutamide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Topiramate is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Topiramate is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of hyperthermia and oligohydrosis can be increased when Biperiden is combined with Topiramate.Approved, Investigational
Biricodar dicitrateThe serum concentration of Topiramate can be increased when it is combined with Biricodar dicitrate.Investigational
BL-1020The risk or severity of adverse effects can be increased when Topiramate is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Blonanserin.Approved, Investigational
BoceprevirThe serum concentration of Topiramate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of hyperthermia and oligohydrosis can be increased when Bornaprine is combined with Topiramate.Experimental
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Topiramate is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Topiramate is combined with Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe serum concentration of Topiramate can be increased when it is combined with Brefeldin A.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Topiramate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Topiramate.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Topiramate is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Topiramate is combined with Bromocriptine.Approved, Investigational
BromotheophyllineTopiramate may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Topiramate is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of hyperthermia and oligohydrosis can be increased when Brompheniramine is combined with Topiramate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of hyperthermia and oligohydrosis can be increased when Buclizine is combined with Topiramate.Approved
BufotenineThe risk or severity of adverse effects can be increased when Topiramate is combined with Bufotenine.Experimental, Illicit
BufyllineTopiramate may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BumetanideThe risk or severity of hypokalemia can be increased when Bumetanide is combined with Topiramate.Approved
BuprenorphineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Topiramate is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Topiramate.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Topiramate.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Topiramate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Topiramate.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Topiramate is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Butylscopolamine is combined with Topiramate.Approved, Investigational, Vet Approved
CabazitaxelThe serum concentration of Topiramate can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cabergoline.Approved
CafedrineTopiramate may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineTopiramate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
CamazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of hyperthermia and oligohydrosis can be increased when Camylofin is combined with Topiramate.Experimental
CanagliflozinThe serum concentration of Topiramate can be increased when it is combined with Canagliflozin.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Topiramate is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Topiramate is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Topiramate is combined with Captodiame.Approved, Investigational
CaptoprilThe serum concentration of Topiramate can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Topiramate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Carbinoxamine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Topiramate is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Topiramate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Topiramate is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Caroxazone.Withdrawn
CarvedilolThe serum concentration of Topiramate can be increased when it is combined with Carvedilol.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Cathinone.Illicit
CefoperazoneThe serum concentration of Topiramate can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Topiramate can be increased when it is combined with Ceftriaxone.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Topiramate is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Topiramate.Approved, Illicit, Investigational
ChlormadinoneThe serum concentration of Chlormadinone can be decreased when it is combined with Topiramate.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroformThe serum concentration of Topiramate can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Topiramate is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypokalemia can be increased when Chlorothiazide is combined with Topiramate.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Chlorphenoxamine is combined with Topiramate.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Chlorpromazine is combined with Topiramate.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of hyperthermia and oligohydrosis can be increased when Chlorprothixene is combined with Topiramate.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypokalemia can be increased when Chlorthalidone is combined with Topiramate.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone.Approved
CilansetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Cilansetron.Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Topiramate.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Topiramate is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Topiramate is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Topiramate can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Clidinium is combined with Topiramate.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Topiramate is combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Topiramate can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Topiramate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Topiramate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Topiramate is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hyperthermia and oligohydrosis can be increased when Clozapine is combined with Topiramate.Approved
CobicistatThe serum concentration of Topiramate can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of hyperthermia and oligohydrosis can be increased when Cocaine is combined with Topiramate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Topiramate.Approved, Illicit
ColchicineThe serum concentration of Topiramate can be increased when it is combined with Colchicine.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Topiramate is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Topiramate is combined with Colistin.Approved
Concanamycin AThe serum concentration of Topiramate can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Topiramate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Topiramate can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Topiramate can be increased when it is combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.Approved
CyclopenthiazideThe risk or severity of hypokalemia can be increased when Cyclopenthiazide is combined with Topiramate.Experimental
CyclopentolateThe risk or severity of hyperthermia and oligohydrosis can be increased when Cyclopentolate is combined with Topiramate.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclosporine.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of hyperthermia and oligohydrosis can be increased when Cycrimine is combined with Topiramate.Approved
CyproheptadineThe risk or severity of hyperthermia and oligohydrosis can be increased when Cyproheptadine is combined with Topiramate.Approved
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Topiramate.Approved, Investigational
DaclatasvirThe serum concentration of Topiramate can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Topiramate can be increased when it is combined with Dactinomycin.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of hyperthermia and oligohydrosis can be increased when Darifenacin is combined with Topiramate.Approved, Investigational
DaunorubicinThe serum concentration of Topiramate can be increased when it is combined with Daunorubicin.Approved
DeanolThe risk or severity of adverse effects can be increased when Topiramate is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Decamethonium.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Demeclocycline.Approved
DemegestoneThe serum concentration of Demegestone can be decreased when it is combined with Topiramate.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Topiramate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Topiramate.Approved
DesipramineThe risk or severity of hyperthermia and oligohydrosis can be increased when Desipramine is combined with Topiramate.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Desloratadine.Approved, Investigational
DesmethylsertralineThe serum concentration of Topiramate can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Topiramate.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Topiramate is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of hyperthermia and oligohydrosis can be increased when Dexetimide is combined with Topiramate.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexmethylphenidate.Approved, Investigational
DexniguldipineThe serum concentration of Topiramate can be increased when it is combined with Dexniguldipine.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Topiramate is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Topiramate is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Topiramate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Topiramate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Topiramate can be increased when it is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Topiramate.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Topiramate is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Topiramate is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Dichloralphenazone.Approved, Illicit
DicyclomineThe risk or severity of hyperthermia and oligohydrosis can be increased when Dicyclomine is combined with Topiramate.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Topiramate.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Topiramate is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Topiramate.Approved, Investigational
DifemerineThe risk or severity of hyperthermia and oligohydrosis can be increased when Difemerine is combined with Topiramate.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Difenoxin.Approved, Illicit
DihexyverineThe risk or severity of hyperthermia and oligohydrosis can be increased when Dihexyverine is combined with Topiramate.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Topiramate.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe serum concentration of Topiramate can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of hyperthermia and oligohydrosis can be increased when Dimetindene is combined with Topiramate.Approved, Investigational
DiphemanilThe risk or severity of hyperthermia and oligohydrosis can be increased when Diphemanil is combined with Topiramate.Experimental
Diphemanil MethylsulfateThe risk or severity of hyperthermia and oligohydrosis can be increased when Diphemanil Methylsulfate is combined with Topiramate.Approved, Vet Approved, Withdrawn
DiphenhydramineThe risk or severity of hyperthermia and oligohydrosis can be increased when Diphenhydramine is combined with Topiramate.Approved, Investigational
DiphenidolThe risk or severity of hyperthermia and oligohydrosis can be increased when Diphenidol is combined with Topiramate.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Topiramate.Approved, Illicit
DipyridamoleThe serum concentration of Topiramate can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dixyrazine.Experimental
DofequidarThe serum concentration of Topiramate can be increased when it is combined with Dofequidar.Experimental, Investigational
DolasetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Topiramate is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Topiramate is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Topiramate is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of hyperthermia and oligohydrosis can be increased when Dosulepin is combined with Topiramate.Approved
DotarizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dotarizine.Investigational
DovitinibThe serum concentration of Topiramate can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxacurium.Approved
DoxazosinThe serum concentration of Topiramate can be increased when it is combined with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hyperthermia and oligohydrosis can be increased when Doxepin is combined with Topiramate.Approved, Investigational
DoxofyllineTopiramate may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Topiramate is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved, Illicit
DronedaroneThe serum concentration of Topiramate can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Topiramate.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Topiramate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Topiramate is combined with Dyclonine.Approved
EconazoleThe serum concentration of Topiramate can be increased when it is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Topiramate is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Topiramate can be increased when it is combined with Elacridar.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Emepronium is combined with Topiramate.Experimental
EmopamilThe serum concentration of Topiramate can be increased when it is combined with Emopamil.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Emylcamate.Experimental
EnasidenibThe serum concentration of Topiramate can be increased when it is combined with Enasidenib.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Topiramate is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone.Approved, Investigational
EntecavirTopiramate may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Topiramate can be increased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Topiramate is combined with Epinastine.Approved, Investigational
EpitizideThe risk or severity of hypokalemia can be increased when Epitizide is combined with Topiramate.Experimental
EplivanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Topiramate is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Topiramate can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Topiramate can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Topiramate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Topiramate is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Topiramate is combined with Esmirtazapine.Investigational
EsomeprazoleThe serum concentration of Topiramate can be increased when it is combined with Esomeprazole.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Topiramate.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Topiramate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Topiramate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Topiramate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Topiramate can be increased when it is combined with Estramustine.Approved, Investigational
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Topiramate.Approved, Investigational
Etacrynic acidThe risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate.Approved, Investigational
EtamiphyllineTopiramate may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EtanautineThe risk or severity of hyperthermia and oligohydrosis can be increased when Etanautine is combined with Topiramate.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethadione.Experimental
EthchlorvynolThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Topiramate.Approved
EthopropazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Ethopropazine is combined with Topiramate.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Topiramate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Topiramate is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Topiramate is combined with Etomidate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Topiramate.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Topiramate can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Topiramate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of hyperthermia and oligohydrosis can be increased when Etybenzatropine is combined with Topiramate.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Topiramate is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Topiramate is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate.Approved
FelodipineThe serum concentration of Topiramate can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineTopiramate may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe serum concentration of Topiramate can be increased when it is combined with Fenofibrate.Approved
FenpiveriniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Fenpiverinium is combined with Topiramate.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Topiramate.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Topiramate is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of hyperthermia and oligohydrosis can be increased when Fesoterodine is combined with Topiramate.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of hyperthermia and oligohydrosis can be increased when Flavoxate is combined with Topiramate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Topiramate can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hyperthermia and oligohydrosis can be increased when Flupentixol is combined with Topiramate.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Topiramate.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Topiramate can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Topiramate is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Topiramate is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Frovatriptan.Approved, Investigational
FurafyllineTopiramate may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of hypokalemia can be increased when Furosemide is combined with Topiramate.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Topiramate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Topiramate is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Topiramate is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of hyperthermia and oligohydrosis can be increased when Gallamine Triethiodide is combined with Topiramate.Approved
GallopamilThe serum concentration of Topiramate can be increased when it is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Topiramate.Approved, Illicit, Investigational
GanciclovirTopiramate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Topiramate is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Topiramate is combined with Gedocarnil.Experimental
GefitinibThe serum concentration of Topiramate can be increased when it is combined with Gefitinib.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Topiramate is combined with Geneticin.Experimental
GenisteinThe serum concentration of Topiramate can be increased when it is combined with Genistein.Investigational
GentamicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Topiramate is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Topiramate is combined with Gepirone.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Topiramate.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Topiramate.Approved
GlecaprevirThe serum concentration of Topiramate can be increased when it is combined with Glecaprevir.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Topiramate is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Topiramate can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Topiramate can be increased when it is combined with Glycerin.Approved, Investigational
GlycopyrroniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Glycopyrronium is combined with Topiramate.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Topiramate can be increased when it is combined with Gramicidin D.Approved
GranisetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.Approved, Investigational
GuanineTopiramate may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Topiramate is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Topiramate is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Topiramate is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Topiramate is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of hyperthermia and oligohydrosis can be increased when Hexocyclium is combined with Topiramate.Approved
HM-30181The serum concentration of Topiramate can be increased when it is combined with HM-30181.Experimental
HomatropineThe risk or severity of hyperthermia and oligohydrosis can be increased when Homatropine is combined with Topiramate.Approved
Homatropine MethylbromideThe risk or severity of hyperthermia and oligohydrosis can be increased when Homatropine Methylbromide is combined with Topiramate.Approved
HycanthoneThe serum concentration of Topiramate can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of hypokalemia can be increased when Hydrochlorothiazide is combined with Topiramate.Approved, Vet Approved
HydrocodoneTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of hypokalemia can be increased when Hydroflumethiazide is combined with Topiramate.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate.Approved, Illicit
HydroxychloroquineThe serum concentration of Topiramate can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Topiramate.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Topiramate is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Hyoscyamine is combined with Topiramate.Approved
HypericinThe risk or severity of adverse effects can be increased when Topiramate is combined with Hypericin.Investigational
HypoxanthineTopiramate may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IbuprofenThe serum concentration of Topiramate can be increased when it is combined with Ibuprofen.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Topiramate is combined with Idalopirdine.Investigational
IdelalisibThe serum concentration of Topiramate can be increased when it is combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Topiramate is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Topiramate is combined with Imagabalin.Investigational
ImatinibThe serum concentration of Topiramate can be increased when it is combined with Imatinib.Approved
ImidafenacinThe risk or severity of hyperthermia and oligohydrosis can be increased when Imidafenacin is combined with Topiramate.Approved, Investigational
ImipramineThe risk or severity of hyperthermia and oligohydrosis can be increased when Imipramine is combined with Topiramate.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Topiramate is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Topiramate is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of hypokalemia can be increased when Indapamide is combined with Topiramate.Approved
IndinavirThe serum concentration of Topiramate can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Topiramate is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Topiramate can be increased when it is combined with Indomethacin.Approved, Investigational
IpratropiumThe risk or severity of hyperthermia and oligohydrosis can be increased when Ipratropium is combined with Topiramate.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Topiramate is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Topiramate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Topiramate is combined with Iproniazid.Withdrawn
IsavuconazoniumThe serum concentration of Topiramate can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Topiramate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Topiramate.Approved, Vet Approved
IsopropamideThe risk or severity of hyperthermia and oligohydrosis can be increased when Isopropamide is combined with Topiramate.Approved, Vet Approved
IsradipineThe serum concentration of Topiramate can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Topiramate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Topiramate can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Topiramate can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Topiramate can be increased when it is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Topiramate.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Topiramate can be increased when it is combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Topiramate is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Lacosamide.Approved
LamotrigineThe risk or severity of hyperthermia and oligohydrosis can be increased when Lamotrigine is combined with Topiramate.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Topiramate is combined with Lanicemine.Investigational
LaniquidarThe serum concentration of Topiramate can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Topiramate can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Topiramate can be increased when it is combined with Lapatinib.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Topiramate is combined with Lasmiditan.Investigational
LedipasvirThe serum concentration of Topiramate can be increased when it is combined with Ledipasvir.Approved
LetermovirThe serum concentration of Topiramate can be increased when it is combined with Letermovir.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Topiramate is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Topiramate is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Topiramate can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Topiramate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Topiramate.Approved
LidocaineThe serum concentration of Topiramate can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Topiramate can be increased when it is combined with Linagliptin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Topiramate is combined with Linezolid.Approved, Investigational
LisofyllineTopiramate may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Topiramate is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Topiramate is combined with Lithium carbonate.Approved
Lithium cationThe serum concentration of Lithium cation can be increased when it is combined with Topiramate.Experimental
LobucavirTopiramate may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Topiramate is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Topiramate can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe serum concentration of Topiramate can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Topiramate can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Topiramate can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Topiramate can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Topiramate can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Topiramate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Lortalamine.Experimental
LosartanThe serum concentration of Topiramate can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Topiramate can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Topiramate.Approved
LumacaftorThe serum concentration of Topiramate can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.Approved, Investigational
LusutrombopagThe serum concentration of Topiramate can be increased when it is combined with Lusutrombopag.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Lymecycline.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Topiramate.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Topiramate is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Topiramate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate.Approved, Investigational
MazaticolThe risk or severity of hyperthermia and oligohydrosis can be increased when Mazaticol is combined with Topiramate.Experimental
MazindolThe risk or severity of adverse effects can be increased when Topiramate is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Mebanazine.Withdrawn
MebeverineThe risk or severity of hyperthermia and oligohydrosis can be increased when Mebeverine is combined with Topiramate.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Topiramate is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Medifoxamine.Experimental
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Topiramate.Approved, Investigational
MefloquineThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Megestrol acetate can be decreased when it is combined with Topiramate.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Topiramate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Topiramate is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Melperone.Approved, Investigational
MepenzolateThe risk or severity of hyperthermia and oligohydrosis can be increased when Mepenzolate is combined with Topiramate.Approved
MephenesinThe risk or severity of adverse effects can be increased when Topiramate is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Topiramate is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Topiramate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Topiramate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Topiramate.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Topiramate is combined with Metergoline.Experimental
MetforminThe risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Methamphetamine.Approved, Illicit
MethanthelineThe risk or severity of hyperthermia and oligohydrosis can be increased when Methantheline is combined with Topiramate.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Topiramate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Topiramate.Approved
MethotrimeprazineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Topiramate is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Methscopolamine is combined with Topiramate.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of hypokalemia can be increased when Methyclothiazide is combined with Topiramate.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Topiramate is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Topiramate is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of hyperthermia and oligohydrosis can be increased when Methylscopolamine bromide is combined with Topiramate.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Topiramate is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Topiramate is combined with Methysergide.Approved
MetixeneThe risk or severity of hyperthermia and oligohydrosis can be increased when Metixene is combined with Topiramate.Approved
MetocurineThe risk or severity of hyperthermia and oligohydrosis can be increased when Metocurine is combined with Topiramate.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Topiramate is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of hypokalemia can be increased when Metolazone is combined with Topiramate.Approved
MetronidazoleThe serum concentration of Topiramate can be increased when it is combined with Metronidazole.Approved
MetyrosineTopiramate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Topiramate can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Topiramate can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Topiramate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Topiramate is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Topiramate is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved, Investigational
MirtazapineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Topiramate can be increased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Topiramate can be increased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumThe risk or severity of hyperthermia and oligohydrosis can be increased when Mivacurium is combined with Topiramate.Approved
MK-212The risk or severity of adverse effects can be increased when Topiramate is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Topiramate is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Topiramate is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Molindone.Approved
MonensinThe serum concentration of Topiramate can be increased when it is combined with Monensin.Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Topiramate is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Topiramate.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Topiramate is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Topiramate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Topiramate is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Topiramate.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Topiramate is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Nefiracetam.Investigational
NelfinavirThe serum concentration of Topiramate can be increased when it is combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Topiramate is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Neosaxitoxin.Investigational
NeratinibThe serum concentration of Topiramate can be increased when it is combined with Neratinib.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hyperthermia and oligohydrosis can be increased when Nicardipine is combined with Topiramate.Approved, Investigational
NigericinThe serum concentration of Topiramate can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Topiramate can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Topiramate can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Topiramate.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Topiramate.Approved
NisoldipineThe serum concentration of Topiramate can be increased when it is combined with Nisoldipine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Topiramate.Approved
NitrendipineThe serum concentration of Topiramate can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Topiramate.Approved, Vet Approved
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Topiramate.Approved, Investigational
NomifensineThe risk or severity of adverse effects can be increased when Topiramate is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Nordazepam.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Topiramate.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Topiramate.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Topiramate.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Topiramate.Approved, Investigational
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Topiramate.Approved
NorgestrienoneThe serum concentration of Norgestrienone can be decreased when it is combined with Topiramate.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hyperthermia and oligohydrosis can be increased when Nortriptyline is combined with Topiramate.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of hyperthermia and oligohydrosis can be increased when Olanzapine is combined with Topiramate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Topiramate is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Topiramate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Ondansetron.Approved
ONT-093The serum concentration of Topiramate can be increased when it is combined with ONT-093.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Topiramate is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Topiramate is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Topiramate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Topiramate is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Topiramate is combined with Osanetant.Investigational
OtiloniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Otilonium is combined with Topiramate.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Topiramate.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of hyperthermia and oligohydrosis can be increased when Oxitropium is combined with Topiramate.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxprenolol.Approved
OxtriphyllineTopiramate may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxybutyninThe risk or severity of hyperthermia and oligohydrosis can be increased when Oxybutynin is combined with Topiramate.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Topiramate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Topiramate.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of hyperthermia and oligohydrosis can be increased when Oxyphencyclimine is combined with Topiramate.Approved
OxyphenoniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Oxyphenonium is combined with Topiramate.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Topiramate can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Topiramate.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Pancuronium is combined with Topiramate.Approved
PantoprazoleThe serum concentration of Topiramate can be increased when it is combined with Pantoprazole.Approved
ParaldehydeTopiramate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Topiramate is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pargyline.Approved
ParitaprevirThe serum concentration of Topiramate can be increased when it is combined with Paritaprevir.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of hyperthermia and oligohydrosis can be increased when Paroxetine is combined with Topiramate.Approved, Investigational
PeldesineTopiramate may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedTopiramate may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Topiramate is combined with Penbutolol.Approved, Investigational
PenciclovirTopiramate may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Topiramate is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.Approved, Vet Approved
PenthienateThe risk or severity of hyperthermia and oligohydrosis can be increased when Penthienate is combined with Topiramate.Experimental
PentifyllineTopiramate may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Topiramate.Approved, Investigational, Vet Approved
PentoxifyllineTopiramate may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
PerazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Topiramate is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Topiramate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Topiramate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Topiramate.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Topiramate is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of hyperthermia and oligohydrosis can be increased when Phenglutarimide is combined with Topiramate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Topiramate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Topiramate is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Topiramate is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Topiramate is combined with Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Topiramate.Approved, Vet Approved
PibrentasvirThe serum concentration of Topiramate can be increased when it is combined with Pibrentasvir.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Topiramate is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Topiramate.Approved
PinazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Topiramate is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Pipecuronium is combined with Topiramate.Approved
PipenzolateThe risk or severity of hyperthermia and oligohydrosis can be increased when Pipenzolate is combined with Topiramate.Experimental
PiperidolateThe risk or severity of hyperthermia and oligohydrosis can be increased when Piperidolate is combined with Topiramate.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of hyperthermia and oligohydrosis can be increased when Pirenzepine is combined with Topiramate.Approved
PiretanideThe risk or severity of hypokalemia can be increased when Piretanide is combined with Topiramate.Approved
PiritramideThe risk or severity of adverse effects can be increased when Topiramate is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Pirlindole.Approved
PitolisantThe serum concentration of Topiramate can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hyperthermia and oligohydrosis can be increased when Pizotifen is combined with Topiramate.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Plazomicin.Approved, Investigational
PoldineThe risk or severity of hyperthermia and oligohydrosis can be increased when Poldine is combined with Topiramate.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Topiramate is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe risk or severity of hypokalemia can be increased when Polythiazide is combined with Topiramate.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Topiramate can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Topiramate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTopiramate may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Topiramate can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Topiramate can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Topiramate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Topiramate is combined with Pridinol.Experimental
PrifiniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Prifinium is combined with Topiramate.Experimental
PrimaquineThe serum concentration of Topiramate can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Topiramate is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.Approved, Vet Approved
ProcyclidineThe risk or severity of hyperthermia and oligohydrosis can be increased when Procyclidine is combined with Topiramate.Approved
ProgabideThe risk or severity of adverse effects can be increased when Topiramate is combined with Progabide.Approved, Investigational
ProgesteroneThe serum concentration of Topiramate can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Promazine is combined with Topiramate.Approved, Vet Approved
PromethazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Promethazine is combined with Topiramate.Approved, Investigational
PropafenoneThe serum concentration of Topiramate can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Topiramate is combined with Propanidid.Experimental
PropanthelineThe risk or severity of hyperthermia and oligohydrosis can be increased when Propantheline is combined with Topiramate.Approved
PropentofyllineTopiramate may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Propiomazine is combined with Topiramate.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hyperthermia and oligohydrosis can be increased when Propiverine is combined with Topiramate.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Topiramate.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Topiramate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Topiramate is combined with Proxibarbal.Experimental
ProxyphyllineTopiramate may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Topiramate is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Topiramate is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Topiramate is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Topiramate is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Topiramate is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Topiramate.Approved, Illicit
QuercetinThe serum concentration of Topiramate can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of hyperthermia and oligohydrosis can be increased when Quetiapine is combined with Topiramate.Approved
QuinacrineThe serum concentration of Topiramate can be increased when it is combined with Quinacrine.Approved, Investigational
QuinethazoneThe risk or severity of hypokalemia can be increased when Quinethazone is combined with Topiramate.Approved
QuingestanolThe serum concentration of Quingestanol can be decreased when it is combined with Topiramate.Experimental
QuinidineThe risk or severity of hyperthermia and oligohydrosis can be increased when Quinidine is combined with Topiramate.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Topiramate is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Topiramate is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Ramosetron.Approved, Investigational
RanitidineThe serum concentration of Topiramate can be increased when it is combined with Ranitidine.Approved
RapacuroniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Rapacuronium is combined with Topiramate.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Topiramate is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Topiramate can be increased when it is combined with Regorafenib.Approved
RemacemideThe risk or severity of adverse effects can be increased when Topiramate is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Topiramate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Topiramate is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Topiramate is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Topiramate.Approved, Investigational
RevefenacinThe risk or severity of hyperthermia and oligohydrosis can be increased when Revefenacin is combined with Topiramate.Investigational
Reversin 121The serum concentration of Topiramate can be increased when it is combined with Reversin 121.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Topiramate can be increased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Topiramate.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Riluzole.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Topiramate can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Rizatriptan.Approved
RociverineThe risk or severity of hyperthermia and oligohydrosis can be increased when Rociverine is combined with Topiramate.Experimental
RocuroniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Rocuronium is combined with Topiramate.Approved
RolapitantThe serum concentration of Topiramate can be increased when it is combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Topiramate is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Romifidine.Vet Approved
RopiniroleTopiramate may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineTopiramate may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Topiramate is combined with RP-5063.Investigational
RucaparibThe serum concentration of Topiramate can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Topiramate.Approved
SafinamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Safrazine.Withdrawn
SalinomycinThe serum concentration of Topiramate can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirThe serum concentration of Topiramate can be increased when it is combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Topiramate is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Topiramate is combined with Sarpogrelate.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Topiramate.Approved
ScopolamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Scopolamine is combined with Topiramate.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Topiramate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Topiramate is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Topiramate is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Topiramate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Topiramate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Topiramate.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SimeprevirThe serum concentration of Topiramate can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Topiramate is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
SolifenacinThe risk or severity of hyperthermia and oligohydrosis can be increased when Solifenacin is combined with Topiramate.Approved
SorafenibThe serum concentration of Topiramate can be increased when it is combined with Sorafenib.Approved, Investigational
St. John's WortThe risk or severity of adverse effects can be increased when Topiramate is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Topiramate can be increased when it is combined with Staurosporine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Topiramate is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Topiramate is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Topiramate is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Topiramate is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Topiramate can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantTopiramate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Topiramate can be increased when it is combined with Tacrolimus.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Topiramate is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Topiramate is combined with Talopram.Experimental
TamoxifenThe serum concentration of Topiramate can be increased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Topiramate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TariquidarThe serum concentration of Topiramate can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Topiramate is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Topiramate is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Topiramate is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Topiramate can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelmisartanThe serum concentration of Topiramate can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Topiramate.Approved, Investigational
TemsirolimusThe serum concentration of Topiramate can be increased when it is combined with Temsirolimus.Approved
TerfenadineThe serum concentration of Topiramate can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Topiramate can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Topiramate can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Topiramate can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Topiramate can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Topiramate can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrahydropalmatine.Investigational
TetrandrineThe serum concentration of Topiramate can be increased when it is combined with Tetrandrine.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrodotoxin.Investigational
ThalidomideTopiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineTopiramate may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineTopiramate may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.Approved
ThonzylamineThe risk or severity of hyperthermia and oligohydrosis can be increased when Thonzylamine is combined with Topiramate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Topiramate can be increased when it is combined with Ticagrelor.Approved
Tiemonium iodideThe risk or severity of hyperthermia and oligohydrosis can be increased when Tiemonium iodide is combined with Topiramate.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tilidine.Experimental
TimepidiumThe risk or severity of hyperthermia and oligohydrosis can be increased when Timepidium is combined with Topiramate.Experimental
TiotropiumThe risk or severity of hyperthermia and oligohydrosis can be increased when Tiotropium is combined with Topiramate.Approved
TipifarnibThe serum concentration of Topiramate can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Topiramate can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Topiramate is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of hyperthermia and oligohydrosis can be increased when Tolterodine is combined with Topiramate.Approved, Investigational
TolvaptanThe serum concentration of Topiramate can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of hypokalemia can be increased when Torasemide is combined with Topiramate.Approved
ToremifeneThe serum concentration of Topiramate can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of hyperthermia and oligohydrosis can be increased when Tramadol is combined with Topiramate.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Topiramate.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of hypokalemia can be increased when Trichlormethiazide is combined with Topiramate.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Topiramate is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Topiramate is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of hyperthermia and oligohydrosis can be increased when Tridihexethyl is combined with Topiramate.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Topiramate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of hyperthermia and oligohydrosis can be increased when Triflupromazine is combined with Topiramate.Approved, Vet Approved
TrihexyphenidylThe risk or severity of hyperthermia and oligohydrosis can be increased when Trihexyphenidyl is combined with Topiramate.Approved
TrimebutineThe risk or severity of hyperthermia and oligohydrosis can be increased when Trimebutine is combined with Topiramate.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Topiramate is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Topiramate can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Topiramate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Topiramate can be increased when it is combined with Troleandomycin.Approved
TropatepineThe risk or severity of hyperthermia and oligohydrosis can be increased when Tropatepine is combined with Topiramate.Experimental
TropicamideThe risk or severity of hyperthermia and oligohydrosis can be increased when Tropicamide is combined with Topiramate.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Topiramate is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of hyperthermia and oligohydrosis can be increased when Trospium is combined with Topiramate.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Topiramate is combined with Tubocurarine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Topiramate.Approved
UmeclidiniumThe risk or severity of hyperthermia and oligohydrosis can be increased when Umeclidinium is combined with Topiramate.Approved
UrapidilThe risk or severity of adverse effects can be increased when Topiramate is combined with Urapidil.Investigational
Uric AcidTopiramate may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Topiramate is combined with Vabicaserin.Investigational
ValaciclovirTopiramate may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Topiramate is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirTopiramate may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValinomycinThe serum concentration of Topiramate can be increased when it is combined with Valinomycin.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Valnoctamide.Investigational
ValomaciclovirTopiramate may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ValpromideThe risk or severity of adverse effects can be increased when Topiramate is combined with Valpromide.Experimental
ValspodarThe serum concentration of Topiramate can be increased when it is combined with Valspodar.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Topiramate is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Topiramate is combined with Vecuronium.Approved
VelpatasvirThe serum concentration of Topiramate can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Topiramate can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Topiramate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Topiramate is combined with Veralipride.Experimental
VerapamilThe serum concentration of Topiramate can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Topiramate is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Vinbarbital.Experimental
VinblastineThe serum concentration of Topiramate can be increased when it is combined with Vinblastine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Topiramate is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Topiramate is combined with Vinylbital.Experimental
VoacamineThe serum concentration of Topiramate can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Topiramate can be increased when it is combined with Vorapaxar.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Vortioxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Topiramate can be increased when it is combined with Voxilaprevir.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Topiramate is combined with Wortmannin.Experimental
XanthineTopiramate may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Topiramate is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Topiramate is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Topiramate is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Topiramate is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Topiramate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Topiramate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Topiramate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Topiramate is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Topiramate is combined with Zolmitriptan.Approved, Investigational
ZolpidemTopiramate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Topiramate can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Topiramate.Approved
ZosuquidarThe serum concentration of Topiramate can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe risk or severity of adverse effects can be increased when Topiramate is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.Approved, Investigational
Food Interactions
  • Following a single dose of the extended-release formulation with a high fat meal, Cmax of topiramate increased by 37% and shortened the Tmax to approximately 8 hours. AUC was not effected. According to the FDA label, Trokendi XR can be taken without regard to food.

References

Synthesis Reference

Orn Almarsson, "Topiramate salts and compositions comprising and methods of making and using the same." U.S. Patent US20040053853, issued March 18, 2004.

US20040053853
General References
  1. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J: Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006 Aug 8;67(3):400-6. [PubMed:16894098]
External Links
Human Metabolome Database
HMDB0005034
KEGG Drug
D00537
KEGG Compound
C07502
PubChem Compound
5284627
PubChem Substance
46508334
ChemSpider
4447672
BindingDB
10887
ChEBI
63631
ChEMBL
CHEMBL220492
Therapeutic Targets Database
DAP000137
PharmGKB
PA451728
HET
TOR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Topiramate
ATC Codes
N03AX11 — Topiramate
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
PDB Entries
3hku / 3lxe / 5jna
FDA label
Download (236 KB)
MSDS
Download (57.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentSleep-Related Eating Disorder1
0TerminatedPreventionEpilepsies / Traumatic Brain Injury (TBI)1
1Active Not RecruitingPreventionCyanotic Congenital Heart Disease1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableSeizures1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedScreeningHealthy Volunteers2
1CompletedTreatmentAlcoholism1
1CompletedTreatmentAlteration of Cognitive Function1
1CompletedTreatmentBMI >30 kg/m21
1CompletedTreatmentBinge Eating Disorder (BED) / Bulimia Nervosa (BN)1
1CompletedTreatmentBipolar Disorder (BD)2
1CompletedTreatmentEpilepsies2
1CompletedTreatmentEpilepsies / Migraines1
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentHuman Volunteers / Migraines1
1Not Yet RecruitingPreventionMigraines1
1Not Yet RecruitingTreatmentContraception / Migraine;Menstrual / Migraines1
1RecruitingBasic ScienceCocaine Use Disorders1
1, 2CompletedTreatmentHypoxic Ischemic Encephalopathy (HIE)1
1, 2CompletedTreatmentSleep Apnea Syndrome1
1, 2RecruitingTreatmentAlcohol Drinking1
2Active Not RecruitingTreatmentBariatric Surgery Procedures / BMI >30 kg/m2 / Metabolic Surgery / Obese experiencing rapid weight loss1
2Active Not RecruitingTreatmentBMI >30 kg/m2 / Obese experiencing rapid weight loss / Obesity, Morbid1
2CompletedNot AvailableTobacco Use Disorders1
2CompletedBasic ScienceAlcoholism1
2CompletedBasic ScienceCocaine-Related Disorders1
2CompletedEducational/Counseling/TrainingBasilar Migraine1
2CompletedTreatmentAlcohol Dependence / Binge Eating1
2CompletedTreatmentAlcohol Dependence / Nicotine Dependence1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentAlcoholism / Dependence, Cocaine1
2CompletedTreatmentBMI >30 kg/m22
2CompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus, Adult-Onset / Type 2 Diabetes Mellitus2
2CompletedTreatmentBinge Eating Disorder (BED)1
2CompletedTreatmentCannabis Abuse / Cannabis Dependence1
2CompletedTreatmentCompulsive Shopping1
2CompletedTreatmentDependence, Cocaine2
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetic Neuropathies / Polyneuropathies / Type 2 Diabetes Mellitus1
2CompletedTreatmentEpilepsies / Epilepsy, Localization Related / Seizures5
2CompletedTreatmentEpilepsy, Absence1
2CompletedTreatmentHeadaches1
2CompletedTreatmentMethamphetamine1
2CompletedTreatmentMigraines2
2CompletedTreatmentSciatica1
2RecruitingTreatmentAlcoholism1
2RecruitingTreatmentCryptogenic Sensory Peripheral Neuropathy1
2RecruitingTreatmentHeadaches / Migraines1
2SuspendedTreatmentBMI >30 kg/m2 / Metabolic Syndromes1
2TerminatedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
2TerminatedTreatmentAlcohol Dependence / Heavy Drinking / Human Immunodeficiency Virus (HIV)1
2TerminatedTreatmentAlcohol Drinking1
2TerminatedTreatmentDrug Induced Dyskinesia / Idiopathic Parkinson's Disease1
2TerminatedTreatmentParkinson's Disease (PD)1
2Unknown StatusTreatmentAlcoholism1
2Unknown StatusTreatmentDisseminated Sclerosis1
2WithdrawnTreatmentGambling1
2, 3CompletedNot AvailableBasilar Migraine1
2, 3CompletedTreatmentAlcohol Dependence2
2, 3CompletedTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
2, 3CompletedTreatmentDependence, Cocaine1
2, 3CompletedTreatmentPosttraumatic Stress Disorders1
2, 3RecruitingTreatmentPTSD and Alcohol Use Disorder1
2, 3Unknown StatusTreatmentAlcohol Dependence / Nicotine Dependence1
3CompletedPreventionChronic Migraine1
3CompletedPreventionHeadaches / Migraines1
3CompletedPreventionMigraines4
3CompletedTreatmentAffective Disorders, Psychotic / Bipolar Disorder (BD) / Moods Disorders1
3CompletedTreatmentAffective Disorders, Psychotic / Bipolar Disorder (BD) / Moods Disorders / Psychiatric Disorder NOS1
3CompletedTreatmentBMI >30 kg/m24
3CompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus, Adult-Onset / Type 2 Diabetes Mellitus2
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
3CompletedTreatmentBinge Eating1
3CompletedTreatmentBipolar Disorder (BD)3
3CompletedTreatmentCessation, Smoking1
3CompletedTreatmentClassic Migraine / Headaches / Migraine Without Aura / Migraines3
3CompletedTreatmentEpilepsies3
3CompletedTreatmentEpilepsies / Epilepsy, Generalized / Epilepsy, Localization Related / Epilepsy, Tonic-Clonic / Seizures1
3CompletedTreatmentEpilepsies / Epilepsy, Generalized / Epilepsy, Localization Related / Seizures1
3CompletedTreatmentEpilepsies / Epilepsy, Localization Related / Seizures2
3CompletedTreatmentEpilepsies / Partial Seizure Disorder / Seizures1
3CompletedTreatmentEpilepsies / Seizures5
3CompletedTreatmentGilles de la Tourette's Syndrome2
3CompletedTreatmentLennox-Gastaut Syndrome (LGS)1
3CompletedTreatmentMigraines2
3CompletedTreatmentMigraines / Vascular Headaches2
3CompletedTreatmentObese Children and Adolescents1
3CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
3CompletedTreatmentTobacco Dependence1
3CompletedTreatmentTremor, Essential1
3RecruitingHealth Services ResearchEpilepsies1
3RecruitingTreatmentAlcohol Dependence1
3RecruitingTreatmentBMI >30 kg/m21
3RecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
3SuspendedTreatmentMetabolic Syndromes / Type 2 Diabetes Mellitus1
3TerminatedPreventionHeadaches / Migraine Disorders / Migraines1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBMI >30 kg/m2 / Diabetes Mellitus, Adult-Onset / Type 2 Diabetes Mellitus1
3TerminatedTreatmentBMI >30 kg/m2 / Hyperlipidemias / Hypertriglyceridemias1
3TerminatedTreatmentEpilepsies / Seizures1
3TerminatedTreatmentPrader-Willi Syndrome1
3Unknown StatusTreatmentAlcohol Dependence / Dependence, Cocaine1
3Unknown StatusTreatmentCocaine-Related Disorders1
3WithdrawnTreatmentAlcohol Dependence / Borderline Personality Disorder (BPD)1
3WithdrawnTreatmentAlcohol Dependence / Post Traumatic Stress Disorder (PTSD)1
4Active Not RecruitingTreatmentBMI >30 kg/m21
4Active Not RecruitingTreatmentEpilepsies1
4CompletedNot AvailableCognitive Deficits1
4CompletedNot AvailableBone destruction / Convulsions / Epilepsies / Osteopenia / Seizures1
4CompletedNot AvailableEpilepsies1
4CompletedNot AvailableMigraines1
4CompletedEducational/Counseling/TrainingRestless Legs Syndrome (RLS)1
4CompletedPreventionMigraine Disorders1
4CompletedPreventionMigraines1
4CompletedTreatmentAlcohol Abuse / Alcoholism / PTSD1
4CompletedTreatmentAlcohol Abuse / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Dependence / Alcoholism / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Drinking1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentBMI >30 kg/m22
4CompletedTreatmentBipolar Disorder (BD) / Cannabis-Related Disorder1
4CompletedTreatmentBipolar Disorder (BD) / Weight gain therapy1
4CompletedTreatmentChronic Migraine2
4CompletedTreatmentClassic Migraine / Headaches / Migraine Without Aura / Migraines1
4CompletedTreatmentEpilepsies3
4CompletedTreatmentEpilepsies / Epilepsy, Generalized / Epilepsy, Localization Related / Grand mal Generalized tonic-clonic seizure / Seizures1
4CompletedTreatmentEpilepsy, Localization Related1
4CompletedTreatmentEpilepsy, Rolandic1
4CompletedTreatmentHazardous and Harmful Alcohol Use / Traumatic Brain Injury (TBI)1
4CompletedTreatmentMigraine Disorders1
4CompletedTreatmentObesity, Childhood / Pediatric Obesity1
4CompletedTreatmentPTSD1
4CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentPosttraumatic Stress Disorders1
4Not Yet RecruitingTreatmentMigraines1
4RecruitingNot AvailableEpilepsies1
4RecruitingTreatmentAlcohol Dependence / Posttraumatic Stress Disorder (PTSD)1
4RecruitingTreatmentAlcohol Use Disorder (AUD)1
4RecruitingTreatmentEpilepsies1
4RecruitingTreatmentObsessive Compulsive Disorder (OCD)1
4RecruitingTreatmentSocial Phobia1
4TerminatedPreventionVomiting1
4TerminatedTreatmentCluster Headache1
4TerminatedTreatmentHeadaches1
4Unknown StatusNot AvailableEpilepsies1
4Unknown StatusPreventionAnalgesic Rebound Headache1
4Unknown StatusTreatmentAlcohol Dependence1
4Unknown StatusTreatmentGlaucoma, Angle-Closure1
4Unknown StatusTreatmentObsessive-Compulsive Disorder (OCD)1
4Unknown StatusTreatmentPathological Gambling1
4WithdrawnTreatmentBulimia Nervosa (BN)1
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableEpilepsies / Seizures1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableMigraine Disorders1
Not AvailableCompletedNot AvailableSeizures, Epileptic1
Not AvailableCompletedTreatmentBMI >30 kg/m21
Not AvailableCompletedTreatmentBulimia Nervosa (BN) / Eating Disorders1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentPatients With Chronic Migraine1
Not AvailableCompletedTreatmentPrader-Willi Syndrome / Self-Injurious Behavior1
Not AvailableCompletedTreatmentRett's Syndrome1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableEpilepsies1
Not AvailableRecruitingTreatmentMigraine Disorders / Vestibular Migraine1
Not AvailableRecruitingTreatmentMigraines1
Not AvailableRecruitingTreatmentSchizophrenia, Schizoaffective Disorder1
Not AvailableSuspendedTreatmentCocaine-Related Disorders / Opioid-Related Disorders1
Not AvailableTerminatedTreatmentAlcohol Abuse / Alcohol Dependence / Alcohol Use Disorder (AUD) / Alcoholism / Posttraumatic Stress Disorders / PTSD1
Not AvailableTerminatedTreatmentParkinson's Disease (PD)1
Not AvailableUnknown StatusNot AvailableHeadaches Chronic / Migraines1
Not AvailableUnknown StatusHealth Services ResearchMigraines1
Not AvailableWithdrawnTreatmentDizziness / Headaches / Migraines1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Cipla ltd
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Torrent pharmaceuticals ltd
  • Unichem laboratories ltd
  • Upsher smith laboratories inc
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Avkare Incorporated
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Camber Pharmaceuticals Inc.
  • Cardinal Health
  • Cipla Ltd.
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • DAVA Pharmaceuticals
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Ethypharm
  • Gallipot
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • InvaGen Pharmaceuticals Inc.
  • Janssen-Ortho Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • McNeil Laboratories
  • Medisca Inc.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Shanghai Junjie Biotechnology Co. Ltd.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • UDL Laboratories
  • Unichem Laboratories Ltd.
  • Upsher Smith Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral50 mg
Capsule, extended releaseOral
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral150 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral25 mg/1
Capsule, extended releaseOral50 mg/1
CapsuleOral15 mg
CapsuleOral25 mg
Tablet, coatedOral100 mg/1
Tablet, coatedOral200 mg/1
Tablet, coatedOral25 mg/1
Tablet, coatedOral50 mg/1
TabletOral100 mg
TabletOral200 mg
TabletOral25 mg
Capsule, coated pelletsOral15 mg/1
Capsule, coated pelletsOral25 mg/1
TabletOral100 mg/1
TabletOral200 1/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral25 meq/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Prices
Unit descriptionCostUnit
Topiramate 200 mg tablet8.32USD tablet
Topamax 200 mg tablet7.68USD tablet
Topiramate 100 mg tablet7.11USD tablet
Topamax 100 mg tablet6.31USD tablet
Topamax 50 mg tablet5.96USD tablet
Topiramate 50 mg tablet5.21USD tablet
Topiramate 25 mg Sprinkle Capsule3.04USD capsule
Topiramate 25 mg tablet2.61USD tablet
Topiramate 99.7% powder2.59USD g
Topiramate 15 mg Sprinkle Capsule2.52USD capsule
Topamax 25 mg tablet2.46USD tablet
Co Topiramate 200 mg Tablet2.08USD tablet
Mylan-Topiramate 200 mg Tablet2.08USD tablet
Novo-Topiramate 200 mg Tablet2.08USD tablet
Phl-Topiramate 200 mg Tablet2.08USD tablet
Pms-Topiramate 200 mg Tablet2.08USD tablet
Ratio-Topiramate 200 mg Tablet2.08USD tablet
Sandoz Topiramate 200 mg Tablet2.08USD tablet
Topamax Sprinkle 25 mg Capsule1.35USD capsule
Sandoz Topiramate 100 mg Tablet1.31USD tablet
Co Topiramate 100 mg Tablet1.31USD tablet
Mylan-Topiramate 100 mg Tablet1.31USD tablet
Novo-Topiramate 100 mg Tablet1.31USD tablet
Phl-Topiramate 100 mg Tablet1.31USD tablet
Pms-Topiramate 100 mg Tablet1.31USD tablet
Ratio-Topiramate 100 mg Tablet1.31USD tablet
Topamax Sprinkle 15 mg Capsule1.29USD capsule
Pms-Topiramate 50 mg Tablet1.05USD tablet
Co Topiramate 25 mg Tablet0.69USD tablet
Mylan-Topiramate 25 mg Tablet0.69USD tablet
Novo-Topiramate 25 mg Tablet0.69USD tablet
Phl-Topiramate 25 mg Tablet0.69USD tablet
Pms-Topiramate 25 mg Tablet0.69USD tablet
Ratio-Topiramate 25 mg Tablet0.69USD tablet
Sandoz Topiramate 25 mg Tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2322644No2005-07-262019-03-01Canada
US5998380Yes1996-04-132016-04-13Us
US6503884Yes1996-04-132016-04-13Us
US7018983Yes1996-04-132016-04-13Us
US7498311Yes1996-04-132016-04-13Us
US7125560Yes1999-09-012019-09-01Us
US6071537No1997-06-232017-06-23Us
US8895057No2008-06-092028-06-09Us
US7056890No2000-06-142020-06-14Us
US7553818No2000-06-142020-06-14Us
US7659256No2000-06-142020-06-14Us
US7674776No2000-06-142020-06-14Us
US8580299No2009-06-142029-06-14Us
US9011906No2008-06-092028-06-09Us
US9011905No2008-06-092028-06-09Us
US8895058No2008-06-092028-06-09Us
US8580298No2009-05-152029-05-15Us
US9101545No2013-03-192033-03-19Us
US8652527No2013-03-192033-03-19Us
US8889190No2013-03-192033-03-19Us
US8889191No2007-11-162027-11-16Us
US8298580No2007-11-162027-11-16Us
US8663683No2007-11-162027-11-16Us
US8877248No2007-11-162027-11-16Us
US8298576No2008-04-042028-04-04Us
US8992989No2007-11-162027-11-16Us
US9555005No2013-03-192033-03-19Us
US9549940No2007-11-162027-11-16Us
US9555004No2007-11-162027-11-16Us
US9622983No2007-11-162027-11-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility9.8 mg/mLNot Available
logP-0.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.8 mg/mLALOGPS
logP1.29ALOGPS
logP0.13ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)11.09ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area115.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.3 m3·mol-1ChemAxon
Polarizability32.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6055
P-glycoprotein substrateNon-substrate0.7905
P-glycoprotein inhibitor INon-inhibitor0.5311
P-glycoprotein inhibitor IINon-inhibitor0.9479
Renal organic cation transporterNon-inhibitor0.9131
CYP450 2C9 substrateNon-substrate0.9479
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.542
CYP450 1A2 substrateNon-inhibitor0.6623
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8674
CYP450 2C19 inhibitorNon-inhibitor0.6539
CYP450 3A4 inhibitorNon-inhibitor0.8469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7952
Ames testAMES toxic0.518
CarcinogenicityNon-carcinogens0.5578
BiodegradationNot ready biodegradable0.9803
Rat acute toxicity2.5682 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-01q9-2960000000-a11a150bcada5055d2e9
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0090000000-c1fa3d6ff15890fc1418
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0059000000-a6337903cab01edce60e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0239000000-994a7b97e101c455a792
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01x0-1970000000-f0e80f5cc5d6fc2b6d38

Taxonomy

Description
This compound belongs to the class of organic compounds known as dioxolopyrans. These are compounds containing a dioxolopyran moiety, which consists of a dioxole ring fused to a pyran ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Dioxolopyrans
Sub Class
Not Available
Direct Parent
Dioxolopyrans
Alternative Parents
Ketals / Oxanes / Monosaccharides / Organic sulfuric acids and derivatives / 1,3-dioxolanes / Oxacyclic compounds / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
Dioxolopyran / Ketal / Oxane / Monosaccharide / Organic sulfuric acid or derivatives / Meta-dioxolane / Oxacycle / Acetal / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cyclic ketal, sulfamate ester, ketohexose derivative (CHEBI:63631)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Nowakowska E, Kus K, Czubak A, Jedrzejewska J: Memory improving and antidepressant effects of topiramate in rats. Arzneimittelforschung. 2009;59(10):487-92. doi: 10.1055/s-0031-1296431. [PubMed:19998575]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002 Mar;49(1):45-8. [PubMed:11948006]
  2. Ceulemans B, Cras P: "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy. Acta Neurol Belg. 2004 Sep;104(3):95-9. [PubMed:15508261]
  3. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L: Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol. 2004 Jul;19(7):516-21. [PubMed:15526956]
  4. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr: Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol. 2007 Feb;22(2):185-94. [PubMed:17621480]
  5. Nieto Barrera M, Candau Fernandez Mensaque R, Nieto Jimenez M: [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects]. Rev Neurol. 2003 Jul 1-15;37(1):64-8. [PubMed:12861512]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated cation channel activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK1
Uniprot ID
P39086
Uniprot Name
Glutamate receptor ionotropic, kainate 1
Molecular Weight
103979.665 Da
References
  1. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H: GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci. 2003 Apr;985:150-62. [PubMed:12724156]
  2. Gryder DS, Rogawski MA: Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003 Aug 6;23(18):7069-74. [PubMed:12904467]
  3. Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. [PubMed:15111016]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
4. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Maryanoff BE, McComsey DF, Costanzo MJ, Hochman C, Smith-Swintosky V, Shank RP: Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7. [PubMed:15771438]
  2. Ma L, Huang YG, Deng YC, Tian JY, Rao ZR, Che HL, Zhang HF, Zhao G: Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice. Life Sci. 2007 Jun 6;80(26):2461-8. Epub 2007 Apr 29. [PubMed:17521680]
  3. Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1726-31. Epub 2007 Jan 8. [PubMed:17251017]
  4. Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5. [PubMed:12617904]
  5. Winum JY, Scozzafava A, Montero JL, Supuran CT: Sulfamates and their therapeutic potential. Med Res Rev. 2005 Mar;25(2):186-228. [PubMed:15478125]
Details
5. Carbonic anhydrase 4
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. [PubMed:14684331]
  2. Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41 Suppl 1:S35-9. [PubMed:10768298]
  3. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. [PubMed:11784136]
  4. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907]
Details
7. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
8. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:18